<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605627</url>
  </required_header>
  <id_info>
    <org_study_id>Oslo University Hospital</org_study_id>
    <nct_id>NCT04605627</nct_id>
  </id_info>
  <brief_title>The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease.</brief_title>
  <acronym>GUT-ACS</acronym>
  <official_title>The Role of Gut Leakage Markers and Microbiota Signature in Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Define a signature of gut microbiota composition and related metabolites in patients with&#xD;
      ST-elevation myocardial infarction, non ST-elevation myocardial infarction and chronic&#xD;
      coronary disease (CAD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 200 patients, allocated to 50 patients with chronic coronary syndrome, 75 patients&#xD;
      with non-ST elevation myocardial infarction and 75 patients with ST- elevation myocardial&#xD;
      infarction will be included. Clinical information, blood samples and fecal samples will be&#xD;
      collected. Fecal and blood samples will be collected once in patients With chronic disease&#xD;
      and in patients with acute coronary syndrome; in the acute phase and after 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiota alpha diversity in myocardial infarction measured as Chao1 Index.</measure>
    <time_frame>Within 7 days from inclusion.</time_frame>
    <description>fecal-sample. 16srRNA (Miseq) will be used for sequencing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Microbiota alpha diversity in myocardial infarction measured as Chao1 Index</measure>
    <time_frame>At 3 months follow-up.</time_frame>
    <description>fecal-sample. 16srRNA (Miseq) will be used for sequencing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipopolysaccharide binding protein (LBP) in myocardial infarction</measure>
    <time_frame>At inclusion</time_frame>
    <description>Blood sample. Analyses will be performed with ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipopolysaccharide binding protein (LBP) in myocardial infarction</measure>
    <time_frame>Change from inclusion to 3 months follow-up.</time_frame>
    <description>Blood sample. Analyses will be performed with ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Soluble cluster of difference-14 in myocardial infarction</measure>
    <time_frame>At inclusion</time_frame>
    <description>Blood sample. Analyses will be performed with ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Soluble cluster of difference-14 in myocardial infarction</measure>
    <time_frame>Change from inclusion to 3 months follow-up.</time_frame>
    <description>Blood sample. Analyses will be performed with ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal fatty acid binding protein-1 in myocardial infarction</measure>
    <time_frame>At inclusion</time_frame>
    <description>Blood sample. Analyses will be performed with ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intestinal fatty acid binding protein-1 in myocardial infarction</measure>
    <time_frame>Change from inclusion to 3 months follow-up.</time_frame>
    <description>Blood sample. Analyses will be performed with ELISA.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Intestinal Disease</condition>
  <arm_group>
    <arm_group_label>Chronic coronary syndrome</arm_group_label>
    <description>50 patients with chronic coronary disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non ST segment-elevation myocardial infarction</arm_group_label>
    <description>75 patients with non ST-elevation myocardial infarction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST-elevation myocardial infarction</arm_group_label>
    <description>75 patients with ST segment-elevation myocardial infarction</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Peripheral blood mononuclear cells (PBMC), feces&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 20-75 years with coronary artery disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Coronary heart disease verified by coronary angiography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current infection requiring intravenous antibiotics&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Renal failure with creatinine &gt; 200µmol/L&#xD;
&#xD;
          -  Hepatic impairment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Previous bariatric surgery&#xD;
&#xD;
          -  Colostomy&#xD;
&#xD;
          -  Active malignant disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marius Trøseid, Md Ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geir Ø Andersen, MD.PhD</last_name>
    <phone>+4791502770</phone>
    <email>g.o.andersen@medisin.uio.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Oslo University Hospital Ullevål</name>
      <address>
        <city>Oslo</city>
        <zip>N-0852</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geir Ø Andersen, Md PhD</last_name>
      <phone>004791502770</phone>
      <email>g.o.andersen@medisin.uio.no</email>
    </contact>
    <contact_backup>
      <last_name>Aasmund Norheim</last_name>
      <phone>004795525854</phone>
      <email>aasmund.norheim@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Geir Ø Andersen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marius Troseid, MD Ass.Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Geir Øystein Andersen</investigator_full_name>
    <investigator_title>MD, PhD, Senior Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Gut leakage</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Chronic coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol, informed consent form (in Norwegian) and clinical study report will be shared by request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data become available 01.06.2022, and will be available until 01.06.2023.</ipd_time_frame>
    <ipd_access_criteria>Requests by email will be answered.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

